This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buller, R. E. Articles by Davis, C. S. Search for Related Content PubMed PubMed Citation Articles by Buller, R. E. Articles by Davis, C. S.

Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival¹

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology [R. E. B., M. S. S., J. P. G., M. Z.] and Department of Pathology [B. R. D. Y.], The University of Iowa Hospitals and Clinics, and Department of Biostatistics, The University of Iowa [C. S. D.] Iowa City, Iowa 52242-1009

Purpose: Many factors modify ovarian cancer survival. There are conflicting reports regarding survival of individuals with hereditary BRCA1-related ovarian cancer. None have controlled for other mechanisms of BRCA1 silencing in the control cohort.

Experimental Design: Fifty-nine cancers with presumed BRCA1 dysfunction because of mutation (24 germ-line and 16 somatic) or absent BRCA1 mRNA because of promoter hypermethylation (n = 19) were identified among 250 consecutively screened ovarian cancers. Controls were matched from the same population based on p53 mutation type, age at diagnosis, Fédération Internationale des Gynaecologistes et Obstetristes surgical stage and histological grade, residual disease, preoperative CA125, disease site, and the presence of BRCA1 mRNA translatable in an in vitro protein expression assay. BRCA1 promoter hypermethylation was determined by the methylation-specific PCR technique. The significance of promoter hypermethylation was confirmed by the absence of detectable BRCA1 mRNA.

Results: The median survival for individuals with ovarian cancer BRCA1 dysfunction was 4.1 years versus 3.5 years in the case matched controls (P = 0.98). Grouped on the basis of the mechanism of BRCA1 dysfunction, median survival was 4.5, 2.8, and 2.3 years for germ-line, somatic, and BRCA1 promoter-silenced ovarian cancers. However, for the corresponding matched controls with wild-type BRCA1 sequence, the median survival was virtually identical: 4.6, 2.8, and 3.3 years, respectively. In a Cox proportional hazards analysis, only residual disease (P = 0.0001), age (P = 0.01), and Fédération Internationale des Gynaecologistes et Obstetristes stage (P = 0.011) entered the survival model.

Conclusions: In contrast with other published reports, we are unable to detect large survival differences between matched case-control cohorts of ovarian cancers with BRCA1 inactivation by any of three independent mechanisms.

This article has been cited by other articles:

				M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer Cancer Res., July 1, 2003; 63(13): 3598 - 3604. [Abstract] [Full Text] [PDF]

				R. A. Jordan, M. T. Preissler, J. A. Banas, and E. J. Gosselin Production of Genetically Engineered Biotinylated Interleukin-2 and Its Application in a Rapid Nonradioactive Assay for T-Cell Activation Clin. Vaccine Immunol., May 1, 2003; 10(3): 339 - 344. [Abstract] [Full Text] [PDF]